NCSTN

Across TCGA pan-cancer cohorts, NCSTN Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCSTN data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher NCSTN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCSTN expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, HNSC, and UCEC are the cancer types where NCSTN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.177	0.712	.006	21	view →
HNSC	DFS	Median	All	0.128	0.710	.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.025	18	view →
BLCA	DFS	Median	IV	0.126	0.479	.007	12	view →
ESCA	OS	Median	All	0.222	0.680	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCSTN–LUSC (DFS)

Open the LUSC breakdown →